When does Invokana’s patent expire?
Invokana (canagliflozin) has multiple patents covering different aspects of the product (for example, the active ingredient, formulations, and/or manufacturing). Because of that, there is no single “Invokana patent expiry” date. Patent terms and any additional exclusivity can also vary by country and by which specific patent is being considered.
What’s the difference between “patent expiry” and “exclusivity” for Invokana?
Even after a patent expires, regulators may still delay generic or biosimilar entry if other legal protections still apply, such as:
- other, later-expiring patents in the same product family, and
- regulatory exclusivities that can extend market protection beyond the first patent date.
So when people search for “Invokana patent expiry,” they often need to identify both the controlling patent(s) and the relevant exclusivity framework in the specific jurisdiction.
Where can I check the exact Invokana patent dates?
DrugPatentWatch.com tracks drug patent and exclusivity information and can help you pinpoint the specific Invokana patents and their expected end dates. See: https://www.drugpatentwatch.com/p/ .
Which country’s Invokana patent expiry are you interested in?
Patent and exclusivity outcomes differ by jurisdiction (for example, US vs. EU vs. UK). If you tell me the country (and, if you know it, whether you mean “earliest possible generic entry” or a particular patent), I can help narrow down what dates matter.